What is HC Wainwright’s Forecast for RYTM Q1 Earnings?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.74) for the quarter, down from their prior estimate of ($0.68). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS and Q1 2026 earnings at ($0.60) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million.

A number of other equities research analysts have also weighed in on the company. Canaccord Genuity Group boosted their target price on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Stifel Nicolaus assumed coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They set a “buy” rating and a $78.00 price objective for the company. Morgan Stanley restated an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. JMP Securities reiterated a “market outperform” rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Finally, The Goldman Sachs Group raised their price target on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $69.46.

Rhythm Pharmaceuticals Stock Down 1.5 %

Rhythm Pharmaceuticals stock opened at $53.49 on Wednesday. The firm has a fifty day simple moving average of $55.25 and a two-hundred day simple moving average of $55.00. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The company has a market capitalization of $3.38 billion, a PE ratio of -12.35 and a beta of 2.30.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Loomis Sayles & Co. L P bought a new stake in shares of Rhythm Pharmaceuticals in the 3rd quarter worth approximately $33,353,000. Janus Henderson Group PLC raised its stake in Rhythm Pharmaceuticals by 103.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock valued at $68,309,000 after buying an additional 621,432 shares during the last quarter. Marshall Wace LLP boosted its holdings in Rhythm Pharmaceuticals by 70.4% in the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company’s stock worth $38,783,000 after acquiring an additional 286,188 shares in the last quarter. Norges Bank purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth $11,512,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Rhythm Pharmaceuticals by 224.3% during the fourth quarter. JPMorgan Chase & Co. now owns 264,585 shares of the company’s stock valued at $14,811,000 after acquiring an additional 182,993 shares in the last quarter.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total transaction of $36,334.70. Following the completion of the transaction, the chief accounting officer now owns 2,070 shares of the company’s stock, valued at approximately $118,445.40. This trade represents a 23.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Yann Mazabraud sold 75,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now directly owns 40,370 shares in the company, valued at $2,078,247.60. This represents a 65.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,131 shares of company stock worth $5,781,098 over the last three months. Company insiders own 5.60% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.